跳转至内容
Merck
CN

F0250000

氟尿嘧啶

European Pharmacopoeia (EP) Reference Standard

别名:

5-氟脲嘧啶, 2,4-二羟基-5-氟嘧啶, 5-FU, 5-氟-2,4(1H,3H)-嘧啶二酮

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C4H3FN2O2
化学文摘社编号:
分子量:
130.08
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
127172
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氟尿嘧啶, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

SMILES string

FC1=CNC(=O)NC1=O

InChI key

GHASVSINZRGABV-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

fluorouracil

manufacturer/tradename

EDQM

mp

282-286 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... TYMS(7298)

正在寻找类似产品? 访问 产品对比指南

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Application

Fluorouracil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral - Carc. 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

André Bp van Kuilenburg et al.
Pharmacogenomics, 14(7), 799-811 (2013-05-09)
5-fluorouracil (5-FU) remains the cornerstone of all currently applied regimens for the treatment of patients with cancers of the gastrointestinal tract, breast, and head and neck. Unfortunately, a large variation in the clearance of 5-FU has been observed between patients
Larissa S Carnevalli et al.
The Journal of experimental medicine, 211(5), 769-779 (2014-04-23)
The serine protease granzyme B (GzmB) is stored in the granules of cytotoxic T and NK cells and facilitates immune-mediated destruction of virus-infected cells. In this study, we use genetic tools to report novel roles for GzmB as an important
Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
Anne Polk et al.
Cancer treatment reviews, 39(8), 974-984 (2013-04-16)
To systematically review the incidence, manifestations and predisposing factors for cardiovascular toxicity in cancer patients treated with systemic 5-fluorouracil or capecitabine. We searched PubMed, EMBASE and Web of science for studies with ≥ 20 cancer patients evaluating cardiovascular toxicity of
Guido Deboever et al.
Clinical colorectal cancer, 12(1), 8-14 (2012-10-30)
Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持